PMID- 24916820
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140612
LR  - 20140611
IS  - 1365-1501 (Print)
IS  - 1365-1501 (Linking)
VI  - 13
IP  - 3
DP  - 2009
TI  - Effectiveness and tolerability of long-acting risperidone: A 9-month open-label 
      extension of a 12-week switching study from oral antipsychotics.
PG  - 192-8
LID - 10.1080/13651500902737000 [doi]
AB  - Objectives. The aim of this non-randomized, single-arm, multi-center, 9-month 
      extension study was to evaluate the maintained efficacy and tolerability of 
      long-acting risperidone injection when we switched to it from previous oral 
      antipsychotics in symptomatically stable patients with schizophrenia or other 
      psychotic disorders. Methods. A total of 98 patients who had completed a previous 
      12-week acute phase study were included. Efficacy and tolerability were assessed 
      with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression 
      (CGI), Global Assessment of Functioning (GAF), and Extrapyramidal Symptom Rating 
      Scale (ESRS). Results. The remission rate of 77.6% (76/98) at baseline and 57.1% 
      (56/98) at the end of the study. Of patients who were in remission at baseline, 
      65.8% (50/76) maintained their remission state until the end. The symptom 
      worsening rate was relatively low (11.1%), and there was no aggravation in mean 
      PANSS total and subscale scores. Spontaneous treatment-emergent adverse events 
      (TEAE) were reported by 21 (21.4%) patients, and most commonly reported adverse 
      events were extrapyramidal symptoms (N=6, 6.1%) and insomnia (N=4, 4.1%). 
      Extrapyramidal symptoms were significantly improved. Conclusions. Switching to 
      long-acting risperidone injection from oral antipsychotics was a safe and 
      well-tolerated strategy for maintaining clinical stability in symptomatically 
      stable patients with schizophrenia.
FAU - Kim, Chang Yoon
AU  - Kim CY
AD  - Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical 
      Center, Seoul, Korea.
FAU - Chung, Seockhoon
AU  - Chung S
FAU - Hahm, Bong-Jin
AU  - Hahm BJ
FAU - Hong, Kyung Sue
AU  - Hong KS
FAU - Yoon, Jin-Sang
AU  - Yoon JS
FAU - Kim, Young-Hoon
AU  - Kim YH
FAU - Bahk, Won-Myong
AU  - Bahk WM
FAU - Lee, Sang-Yeol
AU  - Lee SY
FAU - Lee, Yanghyun
AU  - Lee Y
FAU - Chung, In-Won
AU  - Chung IW
FAU - Kim, Chan-Hyung
AU  - Kim CH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Psychiatry Clin Pract
JT  - International journal of psychiatry in clinical practice
JID - 9709509
OTO - NOTNLM
OT  - Long-acting injection
OT  - maintenance
OT  - remission
OT  - risperidone
EDAT- 2009/01/01 00:00
MHDA- 2009/01/01 00:01
CRDT- 2014/06/12 06:00
PHST- 2014/06/12 06:00 [entrez]
PHST- 2009/01/01 00:00 [pubmed]
PHST- 2009/01/01 00:01 [medline]
AID - 10.1080/13651500902737000 [doi]
PST - ppublish
SO  - Int J Psychiatry Clin Pract. 2009;13(3):192-8. doi: 10.1080/13651500902737000.